Tag : clinical research

Clinical Research, Pharma & Healthcare Financing

Spear Bio Launches Ultra-Sensitive Neurodegenerative Assays

Business Wire
by Business Wire029
Spear Bio, an innovator in ultrasensitive protein biomarker detection, showcased three new SPEAR UltraDetect™ immunoassays—brain-derived p-Tau 217 (BD-pTau 217), α-synuclein (α-syn) and phospho-Ser129-α-synuclein (pS129-α-syn)—at the International...
Clinical Research, Pharma & Healthcare Financing

Gilead to Acquire Ouro Medicines for T Cell Engager Program

Business Wire
by Business Wire034
Acquisition Adds Clinical Stage Bispecific BCMAxCD3 T Cell Engager with Potential for Durable Immune Reset to Gilead’s Inflammation Portfolio Gilead Intends to Enter into a...
Clinical Research, Pharma & Healthcare Financing

Flourish Care Raises $5.7M to Make Doula Care Standard

Business Wire
by Business Wire031
Flourish Care, the maternal healthcare platform with the leading doula network, today announced $5.7 million in oversubscribed seed financing led by Zeal Capital Partners with participation from Create...
Clinical Research, Pharma & Healthcare Financing

Earendil Labs Raises $787M to Scale AI Biologics Development

PR Newswire
by PR Newswire036
Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced that it has raised $787 million in financing rounds. The investment included participation by...
Clinical Research, Pharma & Healthcare Financing

Diamyd Medical Secures $125M Financing, Phase 3 Trial Enrolled

PR Newswire
by PR Newswire043
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG...
Clinical Research, Pharma & Healthcare Financing

Bambusa Therapeutics Appoints Todd James Chief Financial Officer

PR Newswire
by PR Newswire037
– Mr. James brings more than 20 years of biopharmaceutical leadership experience, with deep expertise in capital markets, investor relations, and corporate strategy, serving in...
Clinical Research, Pharma & Healthcare Financing

Congruence Raises $39.5M to Advance Small Molecule Therapies

PR Newswire
by PR Newswire040
– Phase 1/1b clinical trial with CGX-926 ongoing for MC4R-deficient genetic obesity – – Programs in Parkinson’s Disease and Alpha-1 antitrypsin deficiency progressing toward the clinic...
Clinical Research, Pharma & Healthcare Financing

AL-S Pharma Phase 2 Data Shows ALS Program Benefits

Business Wire
by Business Wire023
Results supported by key neuroaxonal injury biomarkers pNfH and NfL after six months of treatment AL-S Pharma’s AP-101 is an investigational human-derived antibody therapeutic that...
Clinical Research, Pharma & Healthcare Financing

Fauna Bio Hits Target Designation in Obesity Collaboration

Business Wire
by Business Wire032
Achievement marks advancement of novel obesity target identified through Convergence™ AI platform Fauna Bio, a biotechnology company pioneering the use of extreme mammal biology and...
Clinical Research, Pharma & Healthcare Financing

C2N Diagnostics First Use of eMTBR-tau243 in Phase 3 Data

Business Wire
by Business Wire028
C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, highlighted the first use of its eMTBR-tau243 plasma assay in a Phase...
Clinical Research, Pharma & Healthcare Financing

Verastem Oncology to Present AVMAPKI FAKZYNJA Combo Therapy

Business Wire
by Business Wire036
Plenary oral presentation features long-term follow-up data from the Phase 2 RAMP 201 recurrent low-grade serous ovarian cancer clinical trial Verastem Oncology (Nasdaq: VSTM), a...
Clinical Research, Pharma & Healthcare Financing

Aarvik Therapeutics Shows Novel ADC Molecules at AACR 2026

Business Wire
by Business Wire050
Aarvik Therapeutics, an innovative, ADC-focused biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce that it will present two posters...
Clinical Research, Pharma & Healthcare Financing

Sanofi’s Venglustat Gets Breakthrough Therapy Status in US

GlobeNewswire
by GlobeNewswire049
Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to venglustat, a novel,...
Clinical Research, Pharma & Healthcare Financing

ONL Therapeutics Treats First EU Patient in GALAXY Phase 2 Trial

PR Newswire
by PR Newswire023
Enrollment begins in Switzerland as the company continues to activate clinical sites beyond the U.S. market ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel...
Clinical Research, Pharma & Healthcare Financing

JAMA Neurology Reports Phase 2b PARADIGM Trial Results in ALS

PR Newswire
by PR Newswire031
The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including...